| Similar Articles |
|---|
 |
Pharmaceutical Executive
July 1, 2012
William Looney |
The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.   |
Pharmaceutical Executive
October 1, 2012
William Looney |
Three Ways to the Future Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Chemistry World
January 6, 2014
Sarah Houlton |
Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed. |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
Chemistry World
September 2009 |
Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Chemistry World
June 17, 2012
Andrew Turley |
Lundbeck to lose 600 jobs The Danish company says it must cut jobs 'to mitigate increased pressure from healthcare reforms, generic competition and uncertainty regarding pricing and reimbursement in Europe'. |
Pharmaceutical Executive
August 1, 2013 |
Country Report: Denmark and Sweden On the Northern fringes of Europe, those who want to believe that there is a sustainable future for the old continent's generous healthcare systems find a beacon of hope. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
October 22, 2009
Robert Steyer |
Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats. |
Chemistry World
March 5, 2013
Andrew Turley |
Alcohol dependence pill approved in EU Danish drug maker Lundbeck has been granted European marketing approval for Selincro (nalmefene) tablets to treat alcohol dependence. |
IndustryWeek
July 20, 2011
Adrienne Selko |
Pharmaceutical's Lean Prescription Facing increasing cost pressures, many pharmaceutical firms are finding a healthy dose of lean the perfect tonic. |
Chemistry World
October 4, 2013
Phillip Broadwith |
Lundbeck cuts jobs in Europe, but expands in US Danish drugmaker Lundbeck is cutting 180-200 jobs in Europe as part of its ongoing restructuring program. However, the company is currently in the process of expanding its staff in the US. |
The Motley Fool
July 18, 2006
Stephen D. Simpson |
Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch. |
Chemistry World
April 2008
Derek Lowe |
Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain. |
The Motley Fool
March 31, 2005
Stephen D. Simpson |
Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look. |
